In June, 2025, the UK government announced plans to boost science and technology research and development (R&D) in the country, pledging to invest £86 billion in the sector over the next 4 years. The ...

The market worth was recorded at $3.16 billion in 2024 and is projected to escalate to $3.68 billion in 2025, unfolding at a robust compound annual growth rate CAGR of 16.1%. The proficient growth in ...

Meanwhile, BioNTech last month telegraphed plans to invest up to 1 billion pounds sterling over the next decade to bolster its R&D operations in the United Kingdom.

BioNTech's all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies, building on BioNTech's proven track record in mRNA research, development ...

With respect to the public offering of BioNTech ADSs to CureVac shareholders in the United Kingdom (the “UK”), BioNTech will publish a UK prospectus exemption document for the purposes of the ...

German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a fresh partner in mRNA specialist BioNTech. | BioNTech plans to invest up ...

The company said its subsidiary BioNTech UK signed a grant agreement with the UK government that builds on a multi-year collaboration announced in January 2023. Under the deal, BioNTech had undertaken ...

The Best Biotech Stocks to Buy Thanks to rapid innovation and strong product launches, some biotech stocks look attractive.

A rare risk of dangerous blood clots associated with the AstraZeneca COVID-19 vaccine was identified and reported in early 2021. This month, the company announced it was pulling the vaccine off ...